Forum: Risks and rewards of gene editing
By Marcy Darnovsky,
Issues in Science and Technology
| 07. 31. 2020
In this interview as in past public comments, Jennifer Doudna opens the door to using the CRISPR platform she helped develop in the service of a hugely controversial enterprise: altering the genomes and traits of future children and subsequent generations. She does so under the banner of responsible science and policy. But as with similar comments by supporters of heritable genome manipulations, her responses shed little light on what criteria would constitute “responsible use,” how irresponsible uses could be avoided, and how this immensely consequential decision might be made in an open and democratically responsible way.
To be sure, Doudna notes that “the main challenge in embryo editing is not scientific … but rather ethical,” and raises important questions about the feasibility of consent by future generations, the difficulty of distinguishing between medical applications and enhancements, and the harm that eradicating genetic conditions might bring to people living with those conditions. But she gives no hint about how these challenges could be met. Tellingly, she fails to mention the broader social justice alarms about heritable genome editing: that the accumulation...
Related Articles
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Judith Levine, The Intercept | 04.04.2024
WHEN THE ALABAMA Supreme Court ruled that fertilized embryos were “extrauterine children,” it did more than imperil the future of in vitro fertilization in Alabama and, potentially, the U.S. The ruling, on the claimed “wrongful death” of frozen embryos...